Introducing the COAPT Trial

Size: px
Start display at page:

Download "Introducing the COAPT Trial"

Transcription

1 physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing the COAPT Trial An assessment of percutaneous mitral valve repair in patients with functional mitral regurgitation who are not appropriate for mitral valve surgery

2 Primary endpoints COAPT Trial design overview Efficacy Device group (MitraClip device) 1 week (post-treatment phone contact) Randomize 1:1 30 days 6, 12, 18, 24 months 430 patients enrolled at up to 85 U.S. sites and Canada Control group (No device) clinical and echo Follow-up a Annually thereafter, for a total of 5 years a TEST: 6MWT, QoL, NYHA functional class, TTE, BNP/nT-pro BNP level, modified Rankin Scale Per protocol 6.0 COAPT Physician Information Brochure version 1.0 October 24, 2014 Recurrent heart failure (HF) hospitalizations through 24 months (analyzed when the last subject completes 12 months of follow-up) Safety Composite of Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, and any device related complications requiring non-elective cardiovascular surgery at 12 months Secondary endpoints Efficacy Mitral regurgitation severity at 12 months Change in 6-minute walk test at 12 months Change in quality of life at 12 months Change in Left Ventricular end-diastolic volume at 12 months NYHA functional class I/II at 12 months Hierarchical composite of death and recurrent HF hospitalization Recurrent hospitalizations all-cause Safety Composite of all-cause death, stroke, MI, or non-elective cardiovascular surgery for device related complications at 30 days post-procedure in the MitraClip group All-cause mortality at 12 months

3 Patient inclusion/exclusion criteria Key inclusion criteria Symptomatic functional MR ( 3+) of either ischemic or nonischemic etiology Subject has been adequately treated per applicable standards, including for coronary artery disease, left ventricular dysfunction, mitral regurgitation and heart failure Not an appropriate candidate for open mitral valve surgery in the judgment of the the local site heart team (CT Surgeon and HF Specialist Investigators) NYHA functional class II, III, or ambulatory IV At least 1 hospitalization for heart failure in the 12 months prior to subject registration and/or a corrected BNP 300 pg/ml or corrected NT-proBNP 1500 pg/ml measured within 90 days prior to subject registration Left Ventricular Ejection Fraction (LVEF) is 20% and 50% Left Ventricular End Systolic Dimension (LVESD) is 70 mm Key exclusion criteria Untreated clinically significant coronary artery disease requiring revascularization Coronary artery bypass grafting (CABG) within prior 30 days Percutaneous coronary intervention within prior 30 days Tricuspid valve disease requiring surgery Aortic valve disease requiring surgery Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy or chronic outpatient oral steroid use Cerebrovascular accident within prior 30 days Severe symptomatic carotid stenosis (> 70% by ultrasound) Carotid surgery within prior 30 days Mitral valve orifice area < 4.0 cm 2 Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets or sufficient reduction in MR by the MitraClip Refer your eligible patients to a COAPT Trial site to enroll. Per protocol 6.0 COAPT Physician Information Brochure version 1.0 October 24, 2014

4 The MitraClip device is a percutaneously implanted mechanical clip. The device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. Placement of the implant is performed without the need for arresting the heart or cardiopulmonary bypass. B Closed double orifice A Open double orifice 1 An implantable clip (A) is delivered into the heart by a catheter (B), via the femoral vein. 2 Once the clip is put into place on the mitral valve, the catheter is removed. CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use only. 3 The clip becomes a permanent implant in the heart, allowing the valve to close tightly and restore normal blood flow through a double-orifice valve.

5 About the COAPT Trial The COAPT Trial is the first prospective, randomized, parallelcontrolled clinical evaluation of the MitraClip device for the treatment of clinically significant functional mitral regurgitation in symptomatic heart failure patients that are not appropriate for mitral valve surgery. The multicenter study will examine the safety and efficacy of the MitraClip device used in addition to standard care for mitral regurgitation and heart failure (device group) compared to treatment with standard care alone (control group). The trial will generate important clinical and economic data to support reimbursement and the development of treatment guidelines.

6 The COAPT Trial is approved Join us in the search for treatment alternatives for patients with functional mitral regurgitation who are not appropriate for mitral valve surgery. Please consider enrolling your eligible patients. For more information on the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) Trial, visit (keyword COAPT ). Abbott Vascular 3200 Lakeside Dr., Santa Clara, CA USA, Tel: COAPT address MitraClip is a registered trademark of the Abbott Group of Companies. Per protocol 6.0 COAPT Physician Information Brochure version 1.0 October 24, Abbott. All rights reserved.

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip

More information

GDMT for percutaneous mitral valve repair

GDMT for percutaneous mitral valve repair GDMT for percutaneous mitral valve repair Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital The 11th Annual Innovations & Trends in Cardiovascular Care New Brunswick, NJ October 18 th 2014 Ted Feldman

More information

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org

More information

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Suzanne V. Arnold, MD, MHA Saint Luke s Mid America

More information

Understanding the guidelines for Interventions in MR. Ali AlMasood

Understanding the guidelines for Interventions in MR. Ali AlMasood Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe

More information

Mitral Regurgitation

Mitral Regurgitation Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical

More information

MitraClip World Wide Commercial Experience

MitraClip World Wide Commercial Experience MitraClip World Wide Commercial Experience Valves Repaired. Lives Improved. Carlos G. Hernandez, MBA Sr. Product Manager, Strategic Planning Abbott Vascular October, 2014 MitraClip Transcatheter Mitral

More information

Preparing for Your Transcatheter Mitral Valve Repair Procedure

Preparing for Your Transcatheter Mitral Valve Repair Procedure WHAT YOU NEED TO KNOW Preparing for Your Transcatheter Mitral Valve Repair Procedure HOW SHOULD YOU PREPARE FOR YOUR PROCEDURE? In the days before your procedure, it is important that you: Take all your

More information

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ Carpentier MV Classification- Leaflet Mobility Normal Increased Decreased Mobility

More information

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve

More information

Percutaneous mitral valve repair: current techniques and results

Percutaneous mitral valve repair: current techniques and results Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Burden of Mitral Regurgitation (MR) in the US Why is This Important? Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence

More information

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS

More information

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES

More information

Prognostic Impact of FMR

Prognostic Impact of FMR Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director

More information

The Counter HF Clinical Study for Heart Failure

The Counter HF Clinical Study for Heart Failure The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure

More information

Management of Secondary MR : Insights from CTSN Ischemic MR trial; COAPT and MITRA-FR:

Management of Secondary MR : Insights from CTSN Ischemic MR trial; COAPT and MITRA-FR: Management of Secondary MR : Insights from CTSN Ischemic MR trial; COAPT and MITRA-FR: Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute,

More information

Organic mitral regurgitation

Organic mitral regurgitation The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality

More information

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,

More information

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M. Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for

More information

Detailed Order Request Checklists for Cardiology

Detailed Order Request Checklists for Cardiology Next Generation Solutions Detailed Order Request Checklists for Cardiology 8600 West Bryn Mawr Avenue South Tower Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable 2018

More information

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,

More information

Repair or Replacement

Repair or Replacement Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non

More information

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural

More information

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the

More information

Adult Echocardiography Examination Content Outline

Adult Echocardiography Examination Content Outline Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,

More information

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty

More information

Mitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN

Mitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Mitral Valve Disease James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Disclosures Affiliation/Financial Relationship Consulting Fees/Honoraria Speaker Bureau Company Abbott, BSC,

More information

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist

More information

APOLLO TMVR Trial Update: Case Presentation

APOLLO TMVR Trial Update: Case Presentation APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure

More information

MitraClip Transcatheter Mitral Valve Repair

MitraClip Transcatheter Mitral Valve Repair MitraClip Transcatheter Mitral Valve Repair A Breakthrough Technology for Your Select High-Surgical-Risk Patients with Severe DMR * Indications: MitraClip Clip Delivery System: The MitraClip Clip Delivery

More information

Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD

Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Disclosures Consultant/Speaker AtriCure Medtronic CryoLife Edwards Abbott Research Funding Abbott Equity Interest Clear Catheter Cleveland Clinic

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

Percutaneous Repair for MR:

Percutaneous Repair for MR: Percutaneous Repair for MR: Follow-up and longer term outcomes Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital 16th ANGIOPLASTY SUMMIT TCT Asia Pacific 2011 April 27-29 th Seoul, Korea Ted Feldman

More information

BrijM ainim D,FA CC ClinicalP rofessorofm edicine. FloridaAtlanticU niversity,bocar aton,fl. R egionalm edicaldirectoroft ranscathetert herapies

BrijM ainim D,FA CC ClinicalP rofessorofm edicine. FloridaAtlanticU niversity,bocar aton,fl. R egionalm edicaldirectoroft ranscathetert herapies BrijM ainim D,FA CC ClinicalP rofessorofm edicine CharlesE.S chm idtco legeofm edicine FloridaAtlanticU niversity,bocar aton,fl R egionalm edicaldirectoroft ranscathetert herapies T enethealthcarecorporation

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural

More information

Learning About Mitral Regurgitation (MR) Causes Symptoms Treatment Options

Learning About Mitral Regurgitation (MR) Causes Symptoms Treatment Options Learning About Mitral Regurgitation (MR) Causes Symptoms Treatment Options How Your Heart Works Your heart pumps blood through your lungs to replenish it with oxygen, and then pumps the oxygen-rich blood

More information

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII I, (Alec Vahanian) DO have a financial interest/arrangement or affiliation

More information

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data

More information

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R

More information

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI Euro Heart Survey New Programme 2009-2012 Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI Alan Cribier, Rouen, France Andreas Gruentzig Award 2010 Cardiogenic

More information

The REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators

The REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial David M Kaye

More information

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Corrective Surgery in Severe Heart Failure Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Session Objectives 1.) Identify which patients with severe

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the

More information

Interventional Updates 2016

Interventional Updates 2016 nterventional Updates 2016 Matthew Johnson, MD Dual Antiplatelet Therapy (DAPT ) What is the newest. Can they ever make up there minds???? What is new in the world of TAVR 1 New risk MitraClip getting

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Indiana Chapter of ACC November 15 th,2008 Percutaneous Mitral Valve Repair James B Hermiller, MD, FACC The Care Group, LLC St Vincent Hospital Indianapolis, IN Mechanisms of Mitral Regurgitation Mitral

More information

Simultaneous Double Clipping Delivery Guide Strategy for Treatment of Severe Coaptation Failure in Functional Mitral Regurgitation

Simultaneous Double Clipping Delivery Guide Strategy for Treatment of Severe Coaptation Failure in Functional Mitral Regurgitation Heart, Lung and Circulation (2015) 24, 98 102 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2014.09.008 HOW-TO-DO-IT Simultaneous Double Clipping Delivery Guide Strategy for Treatment of Severe Coaptation

More information

In Process, Unpublished STS/ACC TVT Registry Manuscripts

In Process, Unpublished STS/ACC TVT Registry Manuscripts In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript

More information

8/31/2016. Mitraclip in Matthew Johnson, MD

8/31/2016. Mitraclip in Matthew Johnson, MD Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ

More information

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado

More information

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions

More information

Transcatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.

Transcatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Transcatheter Mitral Valve Interventions: Clinical Indications Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France. Conflicts of interest: -Consultant for Medtronic -Consultant for Cephea Anatomy of

More information

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure

More information

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This

More information

Cardiology Research Newsletter

Cardiology Research Newsletter in partnership with Cardiology Research Newsletter Fall 2016 Issue Six Percutaneous Approach to Correct Functional Mitral Regurgitation The AccuCinch clinical trial is an early feasibility study designed

More information

Management of TR in Patients Undergoing Mitral Interventions

Management of TR in Patients Undergoing Mitral Interventions Management of TR in Patients Undergoing Mitral Interventions Stephen H. Little, MD John S. Dunn Chair in Cardiovascular Research and Education, Associate professor, Weill Cornell Medicine shlittle@houstonmethodist.org

More information

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated

More information

2019 MITRACLIP CODING AND PAYMENT GUIDE

2019 MITRACLIP CODING AND PAYMENT GUIDE CLAIM 2019 MITRACLIP AND PAYMENT GUIDE MitraClip Transcatheter Mitral Valve Repair Hospital Rates: Effective October 1, 2018 Physician Rates: Effective January 1, 2019 References and Brief Summary 1 CLAIM

More information

1. Technology Name: WATCHMAN Left Atrial Appendage Closure Technology. 3. Trade Brand of Technology: WATCHMAN Left Atrial Appendage Closure Technology

1. Technology Name: WATCHMAN Left Atrial Appendage Closure Technology. 3. Trade Brand of Technology: WATCHMAN Left Atrial Appendage Closure Technology 1. Technology Name: REASANZ (serelaxin) Injection 1 mg/ml Solution for I.V. Infusion 2. Manufacturer Name: Novartis Pharmaceuticals Corporation 3. Trade Brand of Technology: The brand name of the new technology

More information

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction

More information

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Ablation, of mitral leaflets, 80 Accucinch Annuloplasty system, for mitral regurgitation, 79, 94 95 Accutrak delivery system, for CoreValve

More information

Index. B B-type natriuretic peptide (BNP), 76

Index. B B-type natriuretic peptide (BNP), 76 Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible

More information

Update interventional Cardiology Hans Rickli St.Gallen

Update interventional Cardiology Hans Rickli St.Gallen Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter

More information

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; Επιµορφωτικά Σεµινάρια Ειδικευοµένων Καρδιολογίας 7 Απριλίου 2012 M Chrissoheris MD FACC THV Department HYGEIA Hospital Degenerative MR (DMR) Usually refers to an anatomic

More information

FY 2019 HOSPITAL CODING AND PAYMENT GUIDE

FY 2019 HOSPITAL CODING AND PAYMENT GUIDE FY 2019 HOSPITAL CODING AND PAYMENT GUIDE MitraClip Transcatheter Mitral Valve Repair Effective October 1, 2018 Indication for Use: The MitraClip System is indicated for the percutaneous reduction of significant

More information

Current status: Percutaneous mitral valve therapy

Current status: Percutaneous mitral valve therapy Current status: Percutaneous mitral valve therapy Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital ESC Stockholm 2010 Disclosures Research Grants Abbott, Edwards Consultant Abbott, Edwards 2 Percutaneous

More information

Percutaneous Mitral Valve Repair. Transesophageal Echo Acquisition Guide

Percutaneous Mitral Valve Repair. Transesophageal Echo Acquisition Guide TEE Screening MitraClip Percutaneous Mitral Valve Repair Transesophageal Echo Acquisition Guide Suggested Settings n Each view should be performed with and without color flow Doppler using color compare

More information

2018 MITRACLIP PHYSICIAN CODING AND PAYMENT GUIDE

2018 MITRACLIP PHYSICIAN CODING AND PAYMENT GUIDE 2018 MITRACLIP PHYSICIAN CODING AND PAYMENT GUIDE MEDICARE COVERAGE The Centers for Medicare and Medicaid Services (CMS) provide coverage for transcatheter mitral valve repair (TMVr) under Coverage with

More information

Synopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable

Synopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable Synopsis Study title Investigational Product Indication Design of clinical trial Number of trial sites Duration of clinical trial / Timetable Repetitive levosimendan infusions for patients with advanced

More information

Treatment for functional mitral regurgitation

Treatment for functional mitral regurgitation Transcatheter Leaflet Repair for Functional MR What will randomized trials mean for the future of mitral intervention? BY TED FELDMAN, MD, FESC, FACC, MSCAI; PAUL SORAJJA, MD, FACC, FSCAI; PAUL GRAYBURN,

More information

Adult Cardiac Surgery

Adult Cardiac Surgery Adult Cardiac Surgery Mahmoud ABU-ABEELEH Associate Professor Department of Surgery Division of Cardiothoracic Surgery School of Medicine University Of Jordan Adult Cardiac Surgery: Ischemic Heart Disease

More information

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock

More information

2015 Facility and Physician Billing Guide Heart Valve Technologies

2015 Facility and Physician Billing Guide Heart Valve Technologies 2015 Facility and Physician Billing Guide Heart Valve Technologies PHYSICIAN BILLING CODES Clinicians use Current Procedural Terminology (CPT 1 ) codes to bill for procedures and services. Each CPT code

More information

TAVR in 2020: What is Next!!!!

TAVR in 2020: What is Next!!!! TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures

More information

Advanced Mitral Valve Therapies

Advanced Mitral Valve Therapies Advanced Mitral Valve Therapies Mahesh Ramchandani MD, FRCS Chief, Section of Cardiac Surgery A Largely Untreated Patient Population Mitral Regurgitation 2009 U.S. Prevalence Total MR Patients 1,2 4,100,000

More information

Case Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords

Case Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure Petherson Susano Grativvol, 1,2 Katiuska Massucatti Grativvol, 1,2 Alberto de Paula Nogueira Jr., 1,2 João Eduardo Tinoco

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Update on Transcatheter Mitral Valve Repair and Replacment

Update on Transcatheter Mitral Valve Repair and Replacment Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown

More information

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Severe left ventricular dysfunction and valvular heart disease: should we operate? Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict

More information

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

2019 Qualified Clinical Data Registry (QCDR) Performance Measures 2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry

More information

Clinical Trial Coverage Analysis Workshop Practice Device Study

Clinical Trial Coverage Analysis Workshop Practice Device Study Clinical Trial Coverage Analysis Workshop Practice Device Study Aortic Valve Replacement in Extreme Risk Patients with Severe Aortic Stenosis Not Suitable for Standard Open Heart Surgery Replacement Protocol

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

Comprehensive Cardiology: Matters of the Heart Class III SARAH BEANLANDS RN BSCN MSC

Comprehensive Cardiology: Matters of the Heart Class III SARAH BEANLANDS RN BSCN MSC Comprehensive Cardiology: Matters of the Heart Class III SARAH BEANLANDS RN BSCN MSC Overview ACS continued Heart Failure Valvular Disorders and Endocarditis Diagnosis Nuclear stress test- stable angina

More information

MitraClip in the ICCU: Which Patient will Benefit?

MitraClip in the ICCU: Which Patient will Benefit? MitraClip in the ICCU: Which Patient will Benefit? DAVID MEERKIN STRUCTURAL A ND CONGENITAL HEART DISEASE UNIT SHAARE ZEDEK MEDICAL CENTER JERUSALEM Conflict of Interest No relevant disclosures Complex

More information

One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System

One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System Matthias Götberg, MD, PhD On behalf of the LOTUS Edge Investigators: Sabine Bleiziffer, MD; Robert Gooley, MBBS, PhD; Darren L. Walters,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of percutaneous mitral valve leaflet repair for mitral regurgitation Mitral regurgitation

More information

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Steven F Bolling Professor of Cardiac Surgery University of Michigan Optimal Treatment of Functional MR Steven F Bolling Professor of Cardiac Surgery University of Michigan Functional MR Functional MR in Ischemia Badhwar, Bolling, chapter in: Advances in Heart Failure,

More information

2019 ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule

2019 ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule This document and the information contained herein is for general information purposes only and is not intended and does not constitute legal, reimbursement,

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair Policy Number: Original Effective Date: MM.06.027 08/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/01/2017 Section: Surgery Place(s)

More information

Valvular Heart Disease:

Valvular Heart Disease: Oklahoma Heart Institute 1120 South Utica Avenue Tulsa, OK 74104 Valvular Heart Disease: Transcatheter AorticValve Replacement (TAVR) Transcatheter Mitral Valve Repair (TMVR) Oklahoma Heart Institute Physicians

More information